WST — West Pharmaceutical Services Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $399.81
- YTD price return
- +45.31%
- YTD total return
- +45.65%
- Market cap
- 27.9B
- Enterprise value
- 27.7B
- Shares outstanding
- 69.7M
- 52W low
- $223.83
- 52W high
- $438.27
- From 52W high
- -8.78%
- From 52W low
- +78.62%
- 52W range
- 82%$224–$438
- Beta
- 1.13
Volume
- Rel volume
- 0.91×
- 30D volume
- 683.2K
- 30D $ vol
- 267.7M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$5.4M
- Insider net 1Y
- −$6.6M
Form 4 transactions by trade date, as filed; latest on file 2026-09-15.
Fundamentals
- Sales (ttm)
- 3.4B
- Sales/share
- $48.76
- EPS (ttm)
- $8.90
- FCF (ttm)
- 453.4M
- FCF/share
- $6.51
- Book value/share
- $42.61
- Net margin
- 18.81%
- ROE
- 21.52%
- ROA
- 15.73%
- Debt / equity
- 0.07×
- Current ratio
- 2.82
Growth (CAGR, ttm) · 10Y
- Sales
- +12.56%+5.09%+4.85%+8.62%
- Net income
- +29.96%+4.53%+0.85%+16.58%
- FCF
- +19.61%+2.58%+6.10%+25.15%
- Shares
- -3.17%-1.99%-1.22%-0.49%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +31.91%+6.28%+2.00%+17.02%
- Sales/share
- +16.25%+7.22%+6.14%+9.15%
- FCF/share
- +23.54%+4.66%+7.41%+25.77%
- Book value/share
- +0.46%+3.20%+7.47%+10.57%
- Dividend/share
- +6.85%+5.81%+5.79%+6.29%
- Price
- +45.24%+6.28%-0.20%+18.15%
- Total return
- +45.70%+6.58%+0.07%+18.56%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 44.9×
- P/OI (ttm)
- 35.7×
- Fwd P/E
- 39.3×
- P/S (ttm)
- 8.2×
- P/B (mrq)
- 9.4×
- P/FCF (ttm)
- 61.4×
- EV/EBITDA (fy)
- 28.7×
- EV/Sales (ttm)
- 8.2×
- FCF yield (ttm)
- 1.63%
- Dividend yield (fwd)Div yield
- 0.22%
- Dividend yield (ttm)
- 0.22%
- Dividend/share (fwd)
- $0.88
- Buyback yield (realized, 1y)
- 3.17%
- Shareholder yield (realized, 1y)
- 3.51%
- Buyback yield (cash, ttm)
- 2.46%
- Shareholder yield (cash, ttm)
- 2.69%
Vs own 10Y history
- P/E
- 48th
- P/OI
- 47th
- P/S
- 66th
- P/B
- 70th
- P/FCF
- 53rd
Bar = where today’s multiple sits in WST’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +7.5%10Y CAGR +16.4%YoY +59.5%EPS (diluted)
5Y CAGR +8.2%10Y CAGR +18.0%YoY +57.3%Free cash flow
5Y CAGR +9.5%10Y CAGR +19.2%YoY +12.3%TTM: operating cash flow $654.5M, capex −$201.1M
Q3 2026: operating cash flow $189.5M, capex −$39.1M
Shares (diluted)
5Y −4.1%10Y −1.5%YoY −2.5%Dividend per share
5Y CAGR +5.4%10Y CAGR +6.5%YoY +0.0%About West Pharmaceutical Services#
Data provided bySource: Twelve DataWest Pharmaceutical Services Inc. is a healthcare products manufacturer focused on the design, development, and production of containment and delivery systems for injectable drugs and other healthcare products. The company supplies critical components such as stoppers, seals, syringe and cartridge parts, reconstitution and transfer systems, safety and administration devices, and advanced injection solutions that support the packaging and delivery of pharmaceuticals and biologics. It also provides contract manufacturing and analytical lab services through its proprietary and contract-manufactured product segments. West Pharmaceutical Services Inc. serves a broad customer base that includes pharmaceutical, biotechnology, generic-drug, medical device, and consumer healthcare companies. Headquartered in Exton, Pennsylvania, the company plays an important role in the healthcare supply chain by helping enable safe, reliable, and efficient delivery of injectable therapies worldwide.
Exton, PA·10,800 employees·Medical Instruments & Supplies·westpharma.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS $2.66 vs $2.18 est. (+22.0%); revenue $874.5M (+9% y/y) 3.2%
- Sep 8Insider sale · Favorite Annette F (Sr. VP & Chief HR Officer) sold 8,135 shares for $2.8M at $340.81
- Jul 23Earnings · Earnings release — EPS $2.37 vs $2.08 est. (+13.9%); revenue $872.3M (+14% y/y) 0.8%
ETFs holding WST#
35 of the 193 ETFs ChartRow carries live hold WST. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| NOBL | ProShares S&P 500 Dividend Aristocrats ETF | 1.3% |
| VOT | Vanguard Mid-Cap Growth ETF | 0.6% |
| XLV | Health Care Select Sector SPDR Fund | 0.4% |
| VHT | Vanguard Health Care ETF | 0.3% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.2% |
| VO | Vanguard Mid-Cap ETF | 0.2% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| IWR | iShares Russell Midcap ETF | 0.2% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
